Clinical data | |
---|---|
Other names | MK-1022 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII |
Patritumab deruxtecan (U3-1402/ MK-1022) is an experimental antibody–drug conjugate developed by Merck and Daiichi Sankyo to treat non-small-cell lung cancer.[1][2][3]